Skip to main content

Our mission

We create inspired medicines that matter to cancer patients based on our expertise and ADC technologies

Our ADC technology platforms

In our technology platforms, we use a variety of different payloads to research, manufacture and clinically develop highly effective ADCs for the treatment of a variety of malignant hematological and solid tumors. ADCs combine the high affinity and specificity of antibodies with the potency of small toxic molecules to fight cancer.

With our unique expertise in the active ingredient Amanitin from the green death cap mushroom, we have developed a patented and proprietary ATAC technology. The toxin's unique mode of action offers the opportunity to break through drug resistance and eliminate even quiescent tumor cells, which could lead to significant advances in cancer therapy – even for patients who no longer respond to any other treatment.

News

PR: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
26 March 2025
Open
PR: Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
21 March 2025
Open
PR: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
13 March 2025
Open
AH: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
13 March 2025
Open

Meet us

Deutsche Biotechnologietage

9. - 10. April

AACR Annual Meeting

25. - 30. April

Swiss Biotech Day 2025

5. - 6. Mai

Frühjahrskonferenz 2025 - Equity Forum

12. - 14. Mai

Bio International Convention

16. - 19. Juni

    Partner Information

    TitleDate
    Telix: FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
    26 February 2025
    Read more
    Telix: Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
    30 December 2024
    Read more
    Telix: First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients
    28 November 2024
    Read more
    Telix: First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
    3 October 2024
    Read more